Register for January 21st Webinar on Alaska's Oral Parity Campaign
The members of the State Patient Equal Access Coalition (SPEAC) are launching a campaign for oral parity legislation in Alaska. An oral parity bill would require state-regulated private insurance plans to cover patient-administered anticancer treatments (such as oral pills) at an equally favorable rate to physician-administered anticancer treatments (such as intravenous or injectable drugs). To learn more about the oral parity issue, the proposed legislation, and what you can to do to help get it passed, join the informational webinar on January 21st at 2 PM ET / 10 AM PT. Register for the webinar HERE. (Source: Internatio...
Source: International Myeloma Foundation - January 15, 2016 Category: Hematology Source Type: news
The International Myeloma Foundation (IMF) Appoints Dr. Rafat Abonour as New Medical Liaison to Support Organization's European Program Expansion
Myeloma expert Dr. Rafat Abonour as IMF Medical Liaison. Dr. Abonour’s appointment follows the foundation’s recent appointment of French myeloma researcher Prof. Jean-Luc Harousseau, MD. Both men will help accelerate the IMF’s mission to affect positive change around the world. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - January 14, 2016 Category: Hematology Source Type: news
Register Now for TEAM IMF's February 2016 Fundraising Races
Join TEAM IMF during the annual Los Angeles Marathon weekend this February and help us raise money in support of the important Brian D. Novis Research Grants! On Saturday, February 13, 2016, you can enter the LA Big 5K on a course that extends from Elysian Park to Dodger Stadium and back. Those ready to tackle a marathon can opt for the Skechers Performance Los Angeles Marathon on Sunday, February 14, 2016. This 26-mile race starts at Dodger Stadium and ends at the Santa Monica Pier, and can be completed solo or with a relay team of two runners. Click LA Big 5K or Skechers Performance Los Angeles Marathon to register for t...
Source: International Myeloma Foundation - January 12, 2016 Category: Hematology Source Type: news
International Myeloma Foundation (IMF) Accelerates Global Expansion with Appointment of Prof. Jean-Luc Harousseau MD
The International Myeloma Foundation is pleased to announce that renowned myeloma researcher Prof. Jean-Luc Harousseau, MD will join the organization as Medical Education and Research Consultant to help accelerate the IMF's global expansion and outreach efforts in Asia and Europe. With more than 30 years of experience in the field of hematology, Prof. Harousseau was a founding member and served as President of Intergroupe Français du Myélome (IFM), whose clinical trials have significantly contributed to improvements in the prognosis of multiple myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - January 7, 2016 Category: Hematology Source Type: news
Click here to view the replay of the Best of ASH 2015 Teleconference
Now that the American Society of Hematology's (ASH) 2015 annual meeting has come to a close, attendees are sorting through the breadth of knowledge, research, and educational information shared. To simplify the latest trends in myeloma research, the IMF will present a free teleconference: “The Best of ASH 2015: What Patients & Caregivers Need to Know.” Dr. Brian Durie will host this ninety-minute session on Thursday, January 7, 2016, at 4 PM PT / 7 PM ET. If you tune into the teleconference, you will also have a chance to participate—30 minutes of this teleconference will feature a question and answer session with Dr...
Source: International Myeloma Foundation - January 7, 2016 Category: Hematology Source Type: news
Three Holiday Presents for Myeloma Patients
With the recent FDA approvals of the myeloma drugs Darzalex (daratumamab), Ninlaro (ixazomib) and Empliciti (elotuzamab), the end of 2015 offered many holiday presents for myeloma patients. But, as IMF Chairman Dr. Brian Durie writes in his blog this week, in the New Year, myeloma doctors will need to figure out how to use these drugs in a clinical setting. To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 17, 2015 Category: Hematology Source Type: news
Generous Donations Help Fund 2016 Brian D. Novis Research Grants
The IMF awarded its 2016 Brian D. Novis research grants in a ceremony Dec 5, 2015 at the 57th annual meeting of the American Society of Hematology (ASH) in Orlando, FL. For 20 years, the IMF has funded promising clinical investigators in the field of multiple myeloma from around the world through the generous donations of private individuals and IMF Member Fundraisers held across the country. Two very generous surprise donations will undoubtedly help move myeloma research even further ahead! (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 10, 2015 Category: Hematology Source Type: news
ASH 2015 Patients' Perspectives
The IMF's dedicated team of Support Group Leaders from across the US share their observations throughout the ASH meeting at our special “IMF @ ASH” webpage. Their first blog posts focus on the data and events they are looking forward to sharing during the meeting. In addition to blog posts, the IMF ASH team members will share the latest myeloma updates via Twitter (#IMFASH15) and Facebook. To meet the IMF's ASH social media team members, read their first blog posts, and begin following them on social media, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 7, 2015 Category: Hematology Source Type: news
Latest News from the 2015 Annual Meeting of the American Society of Hematology!
The IMF team brings you all the latest news from the 2015 Annual Meeting of the American Society of Hematology (ASH) from Dec. 5th to Dec. 8th in Orlando, FL. Tune into our comprehensive updates via blogs, Facebook, Twitter and IMF-TV to learn about critical myeloma research findings, progress in treatment access around the globe, patients' journeys of hope, and the most promising young myeloma investigators today. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 6, 2015 Category: Hematology Source Type: news
Triple Drug Combination Beats Standard Treatment in Myeloma Trial
A SWOG trial shows bortezomib, lenalidomide, and dexamethasone delays recurrence and lengthens life for myeloma patients, indicating a possible new standard of care. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 5, 2015 Category: Hematology Source Type: news
Addition of bortezomib statistically enhanced the PFS and OS in previously untreated MM
Dr. Brian Durie discussed the randomized phase 3 SWOGG S0777 trial that investigated the addition of bortezomib to lenalidomide and dexamethasone for previously untreated multiple myeloma patients without an intend for immediate autologous stem cell transplant. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 5, 2015 Category: Hematology Source Type: news
Watch the Replay of the IMF's "Point-Counterpoint Session" Broadcast from ASH
(Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 4, 2015 Category: Hematology Source Type: news
Tune in to “Making Sense of Treatment”— a lively debate from ASH 2015 with IMWG doctors
(Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 3, 2015 Category: Hematology Source Type: news
IMF Applauds FDA Approval of Ninlaro (Ixazomib) to Treat Myeloma
Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 20, 2015 Category: Hematology Source Type: news
The FDA approves Ninlaro (ixazomib) to treat patients with relapsed myeloma.
Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 20, 2015 Category: Hematology Source Type: news
